• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Trastuzumab Cures Cancer and Disrupts the Practice of Cardiology.

作者信息

Steingart Richard M, Yu Anthony F, Dang Chau T

机构信息

Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, New York, USA.

出版信息

JACC CardioOncol. 2019 Jul 4;1(1):11-13. doi: 10.1016/j.jaccao.2019.06.002. eCollection 2019 Sep.

DOI:10.1016/j.jaccao.2019.06.002
PMID:34396158
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8352217/
Abstract
摘要

相似文献

1
Trastuzumab Cures Cancer and Disrupts the Practice of Cardiology.曲妥珠单抗治愈癌症并扰乱心脏病学实践。
JACC CardioOncol. 2019 Jul 4;1(1):11-13. doi: 10.1016/j.jaccao.2019.06.002. eCollection 2019 Sep.
2
Cardiology Involvement in Patients with Breast Cancer Treated with Trastuzumab.曲妥珠单抗治疗的乳腺癌患者的心脏受累情况
JACC CardioOncol. 2020 Jun;2(2):179-189. doi: 10.1016/j.jaccao.2020.04.010. Epub 2020 Jun 16.
3
Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.曲妥珠单抗相关心脏毒性与曲妥珠单抗治疗 HER2 阳性转移性乳腺癌患者的心脏监护。
Am J Cardiol. 2020 Apr 15;125(8):1270-1275. doi: 10.1016/j.amjcard.2020.01.029. Epub 2020 Jan 27.
4
Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI.多学科方法在心血管肿瘤学研究试验（MANTICORE 101--乳腺）中新型疗法的原理和设计：一项随机、安慰剂对照试验，旨在使用心脏 MRI 确定常规心力衰竭药物治疗是否可以预防 HER2+早期乳腺癌患者曲妥珠单抗介导的左心室重构。
BMC Cancer. 2011 Jul 27;11:318. doi: 10.1186/1471-2407-11-318.
5
Dilated cardiomyopathy following trastuzumab chemotherapy.曲妥珠单抗化疗后继发扩张型心肌病。
Indian J Pharmacol. 2012 Jan;44(1):131-3. doi: 10.4103/0253-7613.91887.
6
Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study.曲妥珠单抗相关性心肌病：并非看上去那么良性？一项回顾性研究。
J Card Fail. 2009 Oct;15(8):651-7. doi: 10.1016/j.cardfail.2009.04.011. Epub 2009 Jun 27.
7
Impacts of non-recovery of trastuzumab-induced cardiomyopathy on clinical outcomes in patients with breast cancer.曲妥珠单抗诱导性心肌病未恢复对乳腺癌患者临床结局的影响。
Clin Res Cardiol. 2019 Aug;108(8):892-900. doi: 10.1007/s00392-019-01417-x. Epub 2019 Feb 8.
8
First report of trastuzumab treatment after postoperative Takotsubo cardiomyopathy.术后 Takotsubo 心肌病后使用曲妥珠单抗治疗的首例报告。
Anticancer Res. 2014 Jul;34(7):3579-82.
9
Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy.曲妥珠单抗治疗期间发生左心室功能障碍的乳腺癌患者的管理策略和临床结局
Cardiooncology. 2021 Mar 26;7(1):12. doi: 10.1186/s40959-021-00099-7.
10
Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer.
Breast Cancer Res Treat. 2002 Jul;74(2):131-4. doi: 10.1023/a:1016140729725.

引用本文的文献

1
Diagnosis, clinical management, and emerging strategies for coronary artery disease in patients with cancer.癌症患者冠状动脉疾病的诊断、临床管理及新出现的策略
Am Heart J Plus. 2025 Jun 26;56:100568. doi: 10.1016/j.ahjo.2025.100568. eCollection 2025 Aug.
2
Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: Beyond ischemia with non-obstructive coronary arteries (INOCA).癌症靶向治疗和免疫治疗心血管毒性的新见解：超越非阻塞性冠状动脉缺血（INOCA）。
Am Heart J Plus. 2024 Mar 1;40:100374. doi: 10.1016/j.ahjo.2024.100374. eCollection 2024 Apr.
3
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.

本文引用的文献

1
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial.尽管有轻度心脏毒性仍继续使用曲妥珠单抗的安全性：一项I期试验
JACC CardioOncol. 2019 Jul 17;1(1):1-10. doi: 10.1016/j.jaccao.2019.06.004. eCollection 2019 Sep.
2
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.前瞻性评估 HER2 阳性乳腺癌合并心脏功能受损患者 HER2 靶向治疗的心脏安全性：SAFE-HEaRt 研究。
Breast Cancer Res Treat. 2019 Jun;175(3):595-603. doi: 10.1007/s10549-019-05191-2. Epub 2019 Mar 9.
3
Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
SAFE-HEaRt 临床试验中曲妥珠单抗和帕妥珠单抗用于心脏功能受损的乳腺癌患者的心脏安全性的长期随访评估。
Breast Cancer Res Treat. 2021 Feb;185(3):863-868. doi: 10.1007/s10549-020-06053-y. Epub 2021 Jan 5.
4
Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer.辅助性曲妥珠单抗治疗中断对可手术的HER-2阳性乳腺癌患者的临床影响。
Cardiooncology. 2020 Nov 5;6(1):26. doi: 10.1186/s40959-020-00081-9.
曲妥珠单抗治疗 HER2 阳性乳腺癌并左心室射血分数降低患者的心脏结局。
Breast Cancer Res Treat. 2019 May;175(1):239-246. doi: 10.1007/s10549-019-05139-6. Epub 2019 Feb 5.
4
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.HER2阳性早期乳腺癌辅助化疗后曲妥珠单抗的11年随访：HERceptin辅助治疗（HERA）试验的最终分析
Lancet. 2017 Mar 25;389(10075):1195-1205. doi: 10.1016/S0140-6736(16)32616-2. Epub 2017 Feb 17.
5
Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study.早期停用曲妥珠单抗的早期乳腺癌患者的长期心血管结局和总生存率：一项基于人群的研究。
Breast Cancer Res Treat. 2016 Jun;157(3):535-44. doi: 10.1007/s10549-016-3823-y. Epub 2016 Jun 6.
6
Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer.早期HER2阳性乳腺癌中曲妥珠单抗中断与治疗引起的心脏毒性
Breast Cancer Res Treat. 2015 Jan;149(2):489-95. doi: 10.1007/s10549-014-3253-7. Epub 2015 Jan 1.
7
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.6 个月与 12 个月辅助曲妥珠单抗治疗人表皮生长因子受体 2 阳性早期乳腺癌患者（PHARE）的随机 3 期试验
Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11.
8
Duration of adjuvant trastuzumab treatment in routine practice.辅助曲妥珠单抗治疗的持续时间。
Anticancer Res. 2012 Oct;32(10):4585-8.
9
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.NSABP B-31 试验的 7 年心脏功能随访评估，该试验为随机试验，比较了多柔比星和环磷酰胺序贯紫杉醇（ACP）与 ACP 联合曲妥珠单抗用于治疗人表皮生长因子受体 2 阳性、淋巴结阳性乳腺癌患者的辅助治疗。
J Clin Oncol. 2012 Nov 1;30(31):3792-9. doi: 10.1200/JCO.2011.40.0010. Epub 2012 Sep 17.
10
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.曲妥珠单抗相关心脏毒性的可逆性：基于临床病程和药物治疗反应的新见解
J Clin Oncol. 2005 Nov 1;23(31):7820-6. doi: 10.1200/JCO.2005.13.300.